Population Pharmacokinetic Modeling of Oxcarbazepine and Its Active Metabolite 10-Monohydroxy Derivative to Inform Dosing in Children with Obesity
Authors:
- Jaydeep SinhaJSJaydeep Sinha
- Kanecia ZimmermanKZKanecia Zimmerman
- Stephen J. BalevicSBStephen J. Balevic
- Chi HornikCHChi Hornik
- William J. MullerWMWilliam J. Muller
- Mobeen RathoreMRMobeen Rathore
- Marisa MeyerMMMarisa Meyer
- Yaron FinkelsteinYFYaron Finkelstein
- Amira Al-UzriAAAmira Al-Uzri
- Arpita LakhotiaALArpita Lakhotia
- Stuart GoldsteinSGStuart Goldstein
- Jia-Yuh ChenJCJia-Yuh Chen
Open Access
- 17 November 2025
- journal article
- research article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 65 (2) , 329-344
Abstract
Background Oxcarbazepine (OXZ) is an antiepileptic drug whose pharmacological effect is primarily mediated by its active metabolite, 10-monohydroxy derivative (MHD). OXZ is approved for use in adults and children older than 2 years with an age- and body weight-tiered dosing recommendation, but dosing guidance for children with obesity is lacking. Objective This work aimed to assess the dosing requirements of OXZ in children with obesity to support label extension. Methods Two multicenter studies (NCT01431326 and NCT02993861) were conducted in patients receiving standard-of-care OXZ therapy. Participants ≥ 2 years of age with a body mass index ≥ 95th percentile were classified as obese. Plasma concentrations were measured by a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) assay. Nonlinear mixed effects modeling was performed using NONMEM 7.4 to characterize the population pharmacokinetics of OXZ and MHD simultaneously. Simulations were performed to compare MHD systemic exposure in children ≥ 2 years of age with and without obesity. Results One hundred study participants with a median (range) age of 9 years (44 days–20.90 years) contributed 425 plasma concentrations of OXZ (n = 212) and MHD (n = 213). Fifty-two percent of the participants had obesity. A one-compartment joint parent–metabolite model with linear input–output and bi-directional transformation between OXZ and MHD best characterized the pharmacokinetics. Body size was the only covariate affecting pharmacokinetics, and a fat-free mass–based metric termed pharmacokinetic weight (PKWT) best characterized that effect allometrically. Simulation results revealed that the current dosing regimen of OXZ can produce comparable exposure of MHD in children ≥ 2 years of age with and without obesity. Conclusion A model-informed analysis confirms that the current pediatric dosing regimen of OXZ applies to children in general, regardless of their obesity status.Keywords
Funding Information
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (HHSN275201000003I)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD096435)
This publication has 36 references indexed in Scilit:
- Extrapolation of Efficacy from Adults to Pediatric Patients of Drugs for Treatment of Partial Onset Seizures: A Regulatory PerspectiveClinical Pharmacology & Therapeutics, 2022
- Evaluating the Relationship Between Lean Liver Volume and Fat-Free MassClinical Pharmacokinetics, 2019
- The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic ModellingClinical Pharmacokinetics, 2018
- Age‐ and Genotype‐Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate‐Glucuronosyltransferases in Human LiverClinical Pharmacology & Therapeutics, 2018
- Choosing the Allometric Exponent in Covariate Model BuildingClinical Pharmacokinetics, 2018
- Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adultsThe Lancet, 2017
- Prediction of Fat-Free Mass in ChildrenClinical Pharmacokinetics, 2015
- Population pharmacokinetic analysis for 10-monohydroxy derivative of oxcarbazepine in pediatric epileptic patients shows no difference between Japanese and other ethnicitiesDrug Metabolism and Pharmacokinetics, 2015
- Human renal function maturation: a quantitative description using weight and postmenstrual agePediatric Nephrology, 2009
- Changes in liver volume from birth to adulthood: A meta-analysisLiver Transplantation, 2005